← All trials
NCT05475717
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 20, 2022
- Primary completion
- Feb 29, 2024
- Completion date
- May 31, 2024
- First posted
- Jul 27, 2022
- Last posted
- Oct 28, 2022
- Enrollment
- 368
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shijiazhuang Pharma Group (CSPC)Lead sponsor
- Shijiazhuang Pharma Group (CSPC)Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.